Exclusive special offer and discount title banner vector image

GLOBAL NEWCASTLE DISEASE VACCINE MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

REQUEST CUSTOMIZATION

MARKET OVERVIEW

The global Newcastle disease vaccine market is expected to reach $577.29 million by 2032, growing at a CAGR of 8.80% during the forecast period, 2023-2032. The base year considered for the study is 2022, and the estimated period is between 2023 and 2032. The market study has also analyzed the impact of COVID-19 on the global Newcastle disease vaccine market qualitatively as well as quantitatively. 

One of the infectious diseases that has a significant economic impact on the poultry business is Newcastle disease (ND). Chicken and other poultry animals’ respiratory, gastrointestinal, neurological, reproductive, and immunological systems can suffer from severe tissue lesions and significant mortality rates from the highly virulent Newcastle disease virus (NDV). Based on strong biosecurity and widespread vaccination use, considerable progress has been made in decreasing the morbidity and mortality of ND. 

Twenty genotypes of NDV have been identified recently due to its continuous development, and illness outbreaks in chickens that have received vaccinations may be correlated with genetic variation. In some nations, the field spread of aggressive NDV strains is effectively stopped by administering new vaccinations to genotype-matched chickens. Nevertheless, virulent NDV is still widespread in many parts of the world, particularly in low- and middle-income nations, which affects the way of life for millions of people who depend on poultry for a living.

Newcastle Disease Vaccine Market

Read our latest blog on the Poultry Disease Vaccine Market

GROWTH ENABLERS

Key growth enablers of the global Newcastle disease vaccine market growth: 

  • Increasing consumer demand for poultry products
    • Consumption of meat and eggs increased sharply. Population expansion, urbanization, and rising incomes in emerging countries have been the main drivers of growing demand. Additionally, poultry dominates the meat industry due to its widespread affordability, low-fat content, and lack of significant religious and cultural barriers.
    • In addition, according to projections by OECD/FAO Agricultural Outlook 2022-2031, 47% of the protein obtained from meat sources will come from poultry meat. As the rising consumer demands are expected to increase poultry animal consumption and production, it can lead to an increase in Newcastle disease (ND) incidences. 
  • Rising awareness among farmers about vaccination programs’ benefits
  • Government support for animal health research
  • Rising disease outbreaks

GROWTH RESTRAINTS

Key growth restraining factors of the global Newcastle disease vaccine market:

  • High costs of vaccines
  • Inadequate diagnostic facilities
    • Effective disease management and prevention efforts can be significantly hindered by inadequate diagnostic facilities for poultry animals. Diagnosing illnesses like Newcastle disease in chicken flocks can be challenging without access to reliable and precise diagnostic equipment, which can cause delays in treatment and increased risk of disease propagation.
    • Lower production, elevated death rates, and lower market value of infected birds might also result in financial losses for farmers. To solve this problem, investing in better diagnostic facilities and educating veterinarians and poultry farmers to guarantee illness early diagnosis and efficient management is crucial.
  • Stringent regulatory guidelines

To Know More About This Report, Request a Free Sample Copy

DISEASE OVERVIEW

Global Newcastle Disease Vaccine Market | Disease Overview

  • Introduction
  • Symptoms
  • Causes
    • Newcastle disease is a viral infection of bird species caused by virulent strains of avian paramyxovirus serotype 1 (APMV-1). It’s a serious illness that has numerous implications for the poultry business and is infectious. APMV-1 is categorized into three pathotypes depending on its virulence: velogenic (the most virulent), mesogenic (moderately virulent) and lentogenic (the lowest virulent).
    • The velogenic strain is endemic throughout Asia, the Middle East, Africa, and South America. Domestic poultry in other regions, such as Europe, the United States, or Canada, lacks pathogenic strains. When ND outbreaks occur, they must be notified to the government, which leads to sacrificing diseased birds and trade restrictions, which results in severe economic losses.
  • Diagnosis
  • Treatment
    • Live lento genic vaccines, primarily the B1 and LaSota strains, are often employed and are generally sprayed or mixed in large quantities with drinking water and given to birds. Compared to the immunological response caused by an inactivated vaccination, live vaccines administered in these ways elicit mucosal immunity in birds, which minimizes the virulent Newcastle disease virus the vaccinated birds will shed if infected with the same.
    • Individual live vaccination delivery can also be done through the conjunctiva or nares. Young, healthy chicks as young as days 1-4 of life are vaccinated. Immunization can be postponed until the second or third week to avoid maternal antibodies interfering with an active immune response. Moreover, oil-adjuvanted inactivated vaccinations are given to breeders and layers following live immunizations, and they can be given in place of live virus when doing so is potentially inappropriate.

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions:

  • North America: The United States and Canada
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland and Rest of Europe
    • The United Kingdom government ensures a contingency plan for the management and eradication of Newcastle disease, which describes the actions to be undertaken in the case of an epidemic. This involves a surveillance program to track the illness in flocks of poultry and wild birds as well as backup measures for the execution and disposal of affected animals.
    • The Newcastle disease vaccine program in Italy is carried out by the Italian Ministry of Health and the National Reference Center for Newcastle Disease at the Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe). Additionally, the IZSVe offers technical assistance and guidance to poultry farmers, doctors, and other industry participants. They also monitor the illness condition in Italy and carry out research on Newcastle disease.
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global Newcastle disease vaccine market:

  • Bimeda Inc
  • Bio-Med Private Limited
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco Animal Health Inc
  • Hester Biosciences Ltd

REPORT SYNOPSIS

REPORT SCOPE DETAILS
Market Forecast Years 2023-2032
Base Year 2022
Market Historical Years 2018-2022
Forecast Units Revenue ($ Million)
Geographies Analyzed North America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed Merck Animal Health, Zoetis, Ceva Sante Animale, Nisseiken Co, Tianjin Ringpu Bio-Technology Co Ltd, Bio-Med Private Ltd, Boehringer Ingelheim International GmbH, Elanco Animal Health Inc, Phibro Animal Health Corporation, Hester Bioscience Ltd, KM Biologics Co Ltd, Kyoritsu Seiyaku Corporation, Bimeda Inc

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. DISEASE OVERVIEW
    1. INTRODUCTION
    2. SYMPTOMS
    3. CAUSES
    4. DIAGNOSIS
    5. TREATMENT
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING CONSUMER DEMAND FOR POULTRY PRODUCTS
      2. RISING AWARENESS AMONG FARMERS ABOUT VACCINATION PROGRAMS’ BENEFITS
      3. GOVERNMENT SUPPORT FOR ANIMAL HEALTH RESEARCH
      4. RISING DISEASE OUTBREAKS
    2. RESTRAINTS
      1. HIGH COSTS OF VACCINES
      2. INADEQUATE DIAGNOSTIC FACILITIES
      3. STRINGENT REGULATORY GUIDELINES
  5. NEWCASTLE DISEASE PIPELINE ANALYSIS
    1. ANALYSIS BY CANDIDATE
      1. LASOTA
      2. B1 STRAIN
      3. CLONE 30
      4. VG/GA STRAIN
      5. MUKTESWAR STRAIN
    2. ANALYSIS BY DEVELOPMENT APPROACH
      1. DEVELOPMENT OF DNA VACCINES
      2. DEVELOPMENT OF VIRAL VECTOR VACCINES
      3. DEVELOPMENT OF VIRUS-LIKE PARTICLES (VLP) VACCINE
      4. NANOPARTICLE VACCINES
      5. DEVELOPMENT OF NDV REVERSE GENETICS-BASED VACCINES
    3. ANALYSIS BY PHASE
    4. DRUG PROFILING
  6. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. COUNTRY ANALYSIS
        1. UNITED STATES
        2. CANADA
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. COUNTRY ANALYSIS
        1. UNITED KINGDOM
        2. GERMANY
        3. FRANCE
        4. ITALY
        5. SPAIN
        6. BELGIUM
        7. POLAND
        8. REST OF EUROPE
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. COUNTRY ANALYSIS
        1. CHINA
        2. JAPAN
        3. INDIA
        4. SOUTH KOREA
        5. INDONESIA
        6. THAILAND
        7. VIETNAM
        8. AUSTRALIA & NEW ZEALAND
        9. REST OF ASIA-PACIFIC
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REGIONAL ANALYSIS
        1. LATIN AMERICA
        2. MIDDLE EAST & AFRICA
  7. COMPANY PROFILES
    1. BIMEDA INC
    2. BIO-MED PRIVATE LIMITED
    3. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    4. CEVA SANTE ANIMALE
    5. ELANCO ANIMAL HEALTH INC
    6. HESTER BIOSCIENCES LTD
    7. KM BIOLOGICS CO LTD
    8. KYORITSU SEIYAKU CORPORATION
    9. MERCK ANIMAL HEALTH
    10. NISSEIKEN CO LTD
    11. PHIBRO ANIMAL HEALTH CORPORATION
    12. TIANJIN RINGPU BIO-TECHNOLOGY CO LTD
    13. ZOETIS

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – NEWCASTLE DISEASE VACCINE

TABLE 2: GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: NORTH AMERICA NEWCASTLE DISEASE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: NORTH AMERICA NEWCASTLE DISEASE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: EUROPE NEWCASTLE DISEASE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: EUROPE NEWCASTLE DISEASE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC NEWCASTLE DISEASE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC NEWCASTLE DISEASE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: REST OF WORLD NEWCASTLE DISEASE VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: REST OF WORLD NEWCASTLE DISEASE VACCINE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: NORTH AMERICA NEWCASTLE DISEASE VACCINE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 2: UNITED STATES NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 3: CANADA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 4: EUROPE NEWCASTLE DISEASE VACCINE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 5: UNITED KINGDOM NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 6: GERMANY NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 7: FRANCE NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 8: ITALY NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 9: SPAIN NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 10: BELGIUM NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 11: POLAND NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 12: REST OF EUROPE NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC NEWCASTLE DISEASE VACCINE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 14: CHINA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 15: JAPAN NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 16: INDIA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 17: SOUTH KOREA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 18: INDONESIA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 19: THAILAND NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 20: VIETNAM NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 21: AUSTRALIA & NEW ZEALAND NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 22: REST OF ASIA-PACIFIC NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 23: REST OF WORLD NEWCASTLE DISEASE VACCINE MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 24: LATIN AMERICA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 25: MIDDLE EAST & AFRICA NEWCASTLE DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

Like any vaccine, the Newcastle disease vaccine may have mild side effects, such as mild swelling at the injection site or a temporary decrease in egg production. Severe adverse reactions are rare, but it’s essential to follow proper administration techniques and monitor birds after vaccination.

The vaccination schedule for Newcastle disease varies based on the type of vaccine, the age of the birds, and the specific recommendations from the vaccine manufacturer or a poultry veterinarian. Generally, initial vaccinations are given to young birds, followed by booster doses at regular intervals to maintain immunity.

Request Customization
Request Customization
Request free sample